Formula I Compounds Inhibit EWS-FLI1 RHA Helicase A Interaction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for treating glioblastomas and Ewing's Sarcoma Family of Tumors, such as those involving EWS-FLI1, face challenges due to inadequate delivery and stability of antisense and siRNA, necessitating the development of improved methods to target and inhibit key protein interactions for effective cancer treatment.
Innovation Solution
Development of compounds, specifically those of Formula I, which are designed to inhibit the interaction between EWS-FLI1 and RHA helicase A, disrupting oncogenic protein-protein interactions to inhibit tumor growth, and their administration for treating cancers like glioblastoma multiforme and Ewing's Sarcoma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antisense and siRNA are used to target EWS-FLI1, then the oncoprotein expression can be reduced, but the delivery and stability are inadequate for practical human therapy
Solution Approach 1:
The patent uses small molecule compounds as intermediaries that can deliver or facilitate the action of antisense and siRNA molecules. These small molecules act as mediators that improve the stability and delivery of the nucleic acid therapeutics, enabling them to reach their target EWS-FLI1 oncoprotein effectively in human patients.
Solution Approach 2:
The invention combines small molecule compounds with antisense and siRNA molecules to create composite therapeutic agents. This composite approach leverages the stability and cell permeability of small molecules while maintaining the target-specific gene silencing capability of nucleic acids, thereby achieving both improved stability and therapeutic efficacy.
2Productivity
If high doses of chemotherapy are administered to treat Ewing's Sarcoma, then tumor growth may be suppressed, but 75% to 80% of patients with metastatic disease still die within five years
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism driving Ewing's Sarcoma - the EWS-FLI1 oncoprotein formed by chromosomal translocation. By specifically targeting this fusion protein rather than using broad-spectrum chemotherapy, the treatment addresses the root cause of tumor growth while avoiding the limitations of conventional high-dose chemotherapy approaches.
Solution Approach 2:
The invention changes the therapeutic parameter from non-specific high-dose chemotherapy to specific low-dose targeted therapy against EWS-FLI1. This parameter change in treatment specificity and dosage enables effective tumor growth suppression with improved patient survival rates by targeting the unique molecular abnormality in Ewing's Sarcoma.
3Reliability
If standard tri-modality treatment is used for glioblastoma, then some tumor control is achieved, but the infiltrative nature and intrinsic resistance lead to median survival of only 14.6 months
Solution Approach 1:
The patent applies preliminary action by targeting the molecular mechanisms of tumor infiltration and drug resistance before they cause treatment failure. By interfering with protein-protein interactions that enable infiltrative growth and resistance development, the treatment prevents these adverse processes rather than merely responding to them after standard therapy fails.
Solution Approach 2:
The invention uses small molecule compounds that replicate or mimic natural inhibitors of protein-protein interactions. These synthetic molecules copy the function of endogenous regulatory proteins that normally control cell growth and differentiation, thereby restoring normal cellular function in glioblastoma cells and overcoming the limitations of standard tri-modality treatment.
Data Source
AI summary
Methods and compositions provided herein relate to the treatment of cancer. In some embodiments, the compositions have utility in the treatment of cancers including glioblastoma multiforme and lung cancer.